MARKET

RNAC

RNAC

Cartesian
NASDAQ
8.60
-0.91
-9.57%
Closed 19:47 06/15 EDT
OPEN
9.69
PREV CLOSE
9.51
HIGH
9.69
LOW
8.58
VOLUME
260.13K
TURNOVER
0
52 WEEK HIGH
15.57
52 WEEK LOW
5.60
MARKET CAP
252.68M
P/E (TTM)
-1.4581
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAC last week (0608-0612)?
Weekly Report · 1d ago
Cartesian Therapeutics grants new hire stock option for 6,100 shares at $5.86
PUBT · 3d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 3d ago
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
NASDAQ · 3d ago
Cartesian Therapeutics Announces New Employment Inducement Grant
Barchart · 3d ago
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Cartesian Therapeutics (RNAC) and Cullinan Management (CGEM)
TipRanks · 4d ago
Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)
TipRanks · 4d ago
Cartesian Therapeutics Price Target Maintained With a $38.00/Share by Wedbush
Dow Jones · 5d ago
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.